3SBio Inc.
No 3 A1 Road 10
Shenyang Economy & Technology Development Zone
Shenyang,
110027
China - Map
Phone: 86 24 2581 1820
Web Site: http://www.3sbio.com
| 3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People's Republic of China. Its product candidates are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company's principal product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition, the company markets two protein-based therapeutics, Intefen, a recombinant interferon alpha-2a product indicated for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product indicated for the treatment of renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis. Further, the company's product pipeline includes various protein-based therapeutics, including NuPIAO, a second-generation EPIAO product candidate; NuLeusin, a next-generation Inleusin product candidate; TPIAO for the treatment of idiopathic thrombocytopenic purpura; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through a network of distributors to healthcare providers, including hospitals, clinics, and dialysis centers, as well as through distribution agreements with local agents. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Jing Lou , 45
Co-Founder, Chief Exec. Officer |
N/A
| N/A | Ms. Dongmei Su , 37
Chief Technology Officer |
N/A
| N/A | Mr. Ke Li , 40
Corp. Sec. |
N/A
| N/A | Mr. Bin Huang , 46
VP of HR |
N/A
| N/A | Mr. Dan Lou , 72
Co-Founder and Chairman |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.11% Nasdaq 
0.36%
Profile
